Undoubtedly, captopril, along with other ACE inhibitors, has found its place as a first-line therapy of arterial hypertension in leading guidelines [8] and a milestone in the treatment of HF with reduced ejection fraction (EF) [9], bringing about a major improvement in the therapy of these common health states. The gene discussed is ACE; the disease is hydrops fetalis.